The explosion of GLP-1 telehealth platforms since 2023 has been largely positive — access has expanded, prices have come down, and millions of patients who couldn't navigate the traditional healthcare system to get these medications now can. But the same growth has attracted a meaningful number of bad actors: platforms with inadequate medical oversight, hidden fees, poorly sourced compounded medications, and marketing tactics designed to get your credit card, not manage your health.
This guide exists because the warning signs are specific and identifiable. Knowing them protects you from poor care, financial harm, and real medical risk.
Red Flag #1: No Real Physician Review Before Prescribing
The most fundamental safety requirement in GLP-1 telehealth is a licensed clinician — physician, NP, or PA — reviewing your medical history before writing a prescription. This is not a formality. GLP-1 medications have real contraindications:
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome (black box warning — GLP-1 medications are contraindicated)
- Pancreatitis history (GLP-1s are not prescribed in patients with a history of pancreatitis)
- Gallbladder disease (rapid weight loss increases gallstone risk)
- Eating disorders, certain GI conditions, pregnancy or planned pregnancy
A questionnaire-only intake where an algorithm approves your prescription without any clinical judgment applied is not adequate care — it is automated prescription generation. Legitimate providers have a clinician review each new patient case before prescribing, not just flag algorithmic exceptions.
What to check: Before you pay, ask who reviews your intake and what their credentials are. "Our medical team" is not an answer. You should be able to know whether a licensed physician, NP, or PA will personally review your case.
Red Flag #2: No Lab Work Requirements (and No Clear Reasoning Why)
Good GLP-1 prescribing typically involves baseline labs — at minimum, a metabolic panel and A1c — for several reasons:
- GLP-1 medications interact with kidney function (renal impairment affects dosing and tolerability)
- A1c establishes your baseline glucose status and informs the prescribing context
- Liver enzymes can be relevant for patients with fatty liver disease (common comorbidity)
- Lipid panel is relevant for comprehensive metabolic risk assessment
Some legitimate providers operate a "self-report" model that skips labs for straightforward, low-risk cases — that is defensible when combined with robust clinical review of the intake. But if a provider requires no labs, performs minimal clinical review, and still approves prescriptions in minutes, those policies compound to create a pattern of inadequate safety screening.
What to look for: Does the provider explain their lab policy? Do they ask for recent lab results or explain what they screen for in the intake? Can they describe the clinical reasoning behind their protocol?
Red Flag #3: Pricing Isn't Disclosed Until After You've Shared Payment Details
Predatory pricing practices are common in the GLP-1 telehealth market:
- Low advertised monthly costs that exclude medication, lab fees, or required add-ons
- "Subscription" models where cancellation triggers automatic renewal charges
- Hidden fees for consultations, dose adjustments, "expedited shipping," or medication switches
- Auto-refill defaults with confusing cancellation terms
A legitimate provider is transparent about the total monthly cost — medication included — before you enter payment information.
What to do: Before completing checkout, ask: "What is the total monthly cost including medication, any required labs, and shipping?" If the answer changes from what was advertised, that is a red flag.
Red Flag #4: Fake or Misleading Before-and-After Imagery
Before-and-after photos in weight loss marketing are heavily regulated by the FTC — results must be typical, not exceptional, or the atypical nature must be disclosed. In practice, many GLP-1 telehealth marketers use:
- Stock photos sold as genuine patient results
- Extreme results without disclosures about how representative they are
- Before photos that show depressed posture, poor lighting, and unflattering angles compared to high-production after images — a photographic trick rather than health documentation
This matters beyond marketing ethics. Providers who use manipulative imagery to drive conversions are prioritizing revenue over patient trust — and that same incentive often extends to their clinical practices.
What to look for: Do the before-and-after photos include result disclosures ("Results not typical" or similar)? Are the images consistent in quality and production value, or are before photos notably poorer quality than after photos?
Red Flag #5: Vague or Unverifiable Pharmacy Information
For compounded semaglutide or tirzepatide, the pharmacy is the most important safety variable after the prescriber. Patients should be able to identify:
- Which pharmacy compounds or dispenses their medication (by name, not just "our partner pharmacy")
- Whether that pharmacy is properly accredited — PCAB (Pharmacy Compounding Accreditation Board) accreditation is the gold standard for compounders; state pharmacy board licensure is the minimum
- Whether the medication contains the proper active ingredient in proper form — semaglutide base is used in compounded products; "semaglutide sodium" or "semaglutide acetate" are alternative forms whose safety profiles are not established and which the FDA has flagged
A provider who cannot or will not tell you which pharmacy prepares your medication, or who deflects when you ask, is a red flag. Your medication is being injected into your body — knowing where it's made is a basic due diligence question every patient should ask.
Red Flag #6: No Ongoing Clinical Oversight After the First Prescription
GLP-1 therapy requires active management: dose titration over several months, monitoring for side effects, lab follow-up, and response assessment. Patients who don't receive ongoing clinical oversight tend to:
- Stay at starting doses that are too low to achieve meaningful clinical response
- Experience preventable side effects that go unaddressed because there's no one to contact
- Miss signs of complications that warrant medication adjustment or discontinuation
- Lose results that could have been maintained with proper protocol management
Some GLP-1 telehealth platforms are "prescription mills" — they write the first prescription and then the relationship essentially ends. You get medication in the mail but no one is managing your care.
What to ask: "How do dose increases work? Who do I contact if I have significant side effects? What monitoring do you provide after the initial prescription?" The answers should describe an actual protocol, not just a customer service phone number.
Red Flag #7: No Clear Emergency or Complication Protocol
GLP-1 medications have rare but serious potential complications: pancreatitis, gallbladder disease, severe dehydration from vomiting. Patients need to know what to do if they experience:
- Severe abdominal pain that could indicate pancreatitis
- Persistent vomiting that prevents keeping down fluids
- Signs of an allergic reaction
Legitimate providers communicate when to stop the medication and seek emergency care. Providers without any clinical oversight often have no protocol for this — they are medication logistics companies, not healthcare providers.
What Legitimate GLP-1 Telehealth Providers Do
For contrast, here is what good GLP-1 telehealth looks like:
| What Legit Providers Do | What Red-Flag Providers Do |
|---|---|
| Named licensed prescriber reviews your case | Algorithm-only approval |
| Transparent all-in pricing before checkout | Hidden fees revealed after payment |
| Verifiable, accredited pharmacy partner | Unnamed or unverifiable pharmacy |
| Lab work protocol with clinical reasoning | No labs, no explanation |
| Ongoing dose management and monitoring | Write-and-forget prescription model |
| Clear cancellation and refund terms | Confusing or punitive cancellation |
| Documented complication and emergency guidance | No clinical protocols communicated |
| Honest, disclosed-result testimonials | Misleading before/after imagery |
How TeleHealth Ally Vets Every Provider
The TeleHealth Ally provider directory exists because the research burden is real and consequential. Every provider listed in our directory has been reviewed against our vetting checklist:
- Licensed clinician involvement verified (physician or qualified NP/PA)
- Pricing transparency confirmed — all fees documented before checkout
- Pharmacy partners identified and checked for state licensure and accreditation
- Clinical follow-up available and described clearly
- Patient safety protocols in place for contraindications and complications
- No outstanding safety complaints in publicly available records or verified user reports
We do not accept paid placements in exchange for directory inclusion — providers are listed based on our vetting standards, not marketing budgets. Providers can be removed at any time if they no longer meet our standards.
If you're ready to find a vetted provider, take our free matching quiz to get matched to options that fit your clinical situation, location, and budget.
The Bottom Line
The GLP-1 telehealth space has more bad actors than most patients expect. The red flags above are specific and mostly visible before you commit to a provider — use them. The investment in evaluating a provider carefully upfront is significantly less costly than discovering problems after months of subscription charges, inadequate care, or a medication-related complication with no clinical backup.
For more on navigating the GLP-1 landscape, see our full guide to GLP-1 telehealth vs in-person care and our best GLP-1 telehealth providers overview.
This article is for informational and consumer education purposes only. TeleHealth Ally does not provide medical advice, and provider listings in our directory are not medical endorsements. Always consult a licensed healthcare provider before starting or changing any medication regimen. Provider listing standards are reviewed periodically and reflect our assessment at the time of publication.